The changing landscape of Research and Development

Over the past decade, the development of innovative medicines has changed dramatically. This IQVIA report evaluates research and development (R&D) activity and landscape, clinical development process productivity levels, and how key trial trends will reshape clinical development over the next five years. The characteristics and development path of both newly launched therapies and pipeline therapies are examined along with the company transitions that bring these drugs to the market. This report presents a proprietary index of clinical development productivity reflecting changes in the complexity, success and duration of trials over time.

Key findings

1. Of the new active substances launched in 2018, 46% were approved based on data from trials with fewer than 500 total subjects
2. Emerging biopharma companies now account for over 70% of the total late stage R&D pipeline
3. Composite success rates varied by therapy area between 6−15% in 2018, with rates for rare diseases and GI/NASH exceeding averages
4. Eight key trends are influencing aspects of trial design, duration and success
5. Biomarkers will have the greatest impact on clinical productivity yielding a 34% average increase across all phases of development

Source: www.iqvia.com